Xue-feng Bai, MD, PhD
College of Medicine
>Cancer ● Encephalomyelitis, Autoimmune, Experimental ● Neuritis, Autoimmune, Experimental ● Multiple Sclerosis ● Myasthenia Gravis, Autoimmune, Experimental ● Autoimmune Diseases ● Plasmacytoma
Xue-Feng Bai, MD, PhD, is a member of the Translational Therapeutics Program at the OSUCCC – James, where his research focuses on investigation of tumor immune microenvironment and development of novel immunotherapy.Recently, Dr. Bai published a paper in the Journal of Immunology and found that CD200 receptor signaling can significantly shape the tumor microenvironment and affect the induction of tumor-specific T-cell responses. Based on these observations, his team is investigating the underlying mechanisms and developing strategies to target CD200 receptor in cancer. Dr. Bai’s research has appeared in prestigious publications, including Cancer Research, Journal of Immunology, Blood, Journal of Clinical Investigation, Journal of Experimental Medicine, Clinical Cancer Research and OncoImmunology.